The hippocampus is critical for learning and memory contains neural progenitor cells (npcs). The hippocampus continues to generate new neurons throughout life, a process is Known as adult hippocampal neurogenesis (AHN). Hippocampal neurogenesis is persistent Through the tenth decade of human life, and is detectable in patients with Alzheimer’s disease (AD). There was a marked and progressive decline of DCX+ cell numbers in AD patients as Compared with neurologically healthy individuals. AHN impairment compromises hippocampal Function in AD and MCI. This indicates that reduced AHN causes memory impairments and Cognitive deterioration in the disease. It was observed that AHN impairment take place prior to the presence of senile plaques and neurofibrillary tangles (nfts), both of which are key Pathological hallmarks of AD, in the dentate gyrus. We proposed that stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic Resilience.

To illustrate the guidance of the neurogenesis hypothesis, we reviewed a case study using the Results of the Phase 2A study of NA-831 for the treatment of Alzheimer’s disease. NA-831 is a Small drug molecule, easily crosses the blood brain barrier with excellent bioavailability. The Drug exhibits neuroprotection, neurogenesis and memory enhancing properties. A randomized clinical trial of NA-831 was performed in 112 participants with mild and Moderate Alzheimer’s disease, half received the drugs and half received placebo. The patients With MCI received 10 mg of NA-831 or placebo orally per day. The patients with mild and Moderate Alzheimer’s disease received 30 mg of NA-831 or placebo orally per day. Subjects with MCI to meet the NIA-AA core clinical criteria for mild cognitive impairment due To Alzheimer’s disease. CDR score of 0.5 and a Memory Box score of 0.5 or greater at Screening And Baseline. MMSE score ≥22. Subjects with mild & moderate Alzheimer’s disease to meet the NIA-AA core clinical criteria for probable Alzheimer’s disease dementia. MMSE: 17-21.

NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog-13 score change of an average of 4.1 as compared to the placebo after 24 weeks of Treatment (p = 0.001; ITT). CIBIC-Plus showed 78 % patients improved (p = 0.01; ITT). Mna- 831 was well-tolerated at 30 mg/day. There were no serious adverse events observed. The Neurogenesis Hypothesis has been shown to be a viable approach for further research for Alzheimer’s disease and other neurodegenerative diseases.

Biomed is in the process of Conducting a Phase 2B and Phase 3 trials of NA-831 in 2023. A more supportive environment Will encourage the generation of new hypotheses and development of novel drugs that will bring Hope to millions of patients of Alzheimer’s disease